Cevimeline

This page contains recent news articles, when available, and an overview of Cevimeline but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Cevimeline (when available)

Pharmacology and use:
Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome

Mechanism Of Action:
Muscarinic agonists such as cevimeline in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.

News Articles on Cevimeline

Syndrome can cause dry eyes and mouth - Sep 28, 2008
There are two drugs available that stimulate the salivary glands to produce saliva: pilocarpine (Salagen) and cevimeline (Evoxac). Daytona Beach News-Journal,

Dry eyes and dry mouth are signs of Sjogren's syndrome - May 22, 2007
SouthCoastToday.com,Pilocarpine (Salagen) and cevimeline (Evoxac) are pills that promote saliva production. Your wish has been fulfilled by the Sjogren's Syndrome Foundation,

Brand Names/Synonyms:
Cevimeline is also known by the following brand names and/or synonymsAF 102B; AF-102B; Cevimeline; Cevimeline Hydrochloride; Cevimeline Hydrochloride Hydrate; Cevimeline, Hydrochloride Salt; Cevimelinehydrochloride Salt; Evoxac; Fks 508; Sni 2011

Drug Category:
Cevimeline is categorized under the following by the FDA: Parasympathomimetics; Muscarinic Agonists

Dosage Forms:
Not Available

Absorption:
Rapidly absorbed with peak concentration after 1.5 to 2 hours

Interactions:
Interactions for Cevimeline:

Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects. Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.

Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events. In an in vitro study, cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline.

Chemical IUPAC Name:
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.